C4 Therapeutics Inc (CCCC) Stock Price, Quote & News

Company Profile

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epi...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 231 0700

Website: www.c4therapeutics.com

Address:

490 Arsenal Way, Suite120, Watertown, United States

zawojak Mar. 16 at 10:43 PM

$CCCC The EGFR L858R degrader CFT8919 has Phase 1 China data expected this quarter with a company decision due this month on whether to pursue development or partner, while C4 reports just under $300 million of runway through the end of 2028. Potential small catalyst.

0 · Reply

zawojak Mar. 16 at 7:24 PM

$CCCC shorts interest over 8.5M and growing, we are getting noticed.

0 · Reply

Stockboi_ Mar. 16 at 3:46 PM

$CCCC could be time for reversal here

0 · Reply

lelongduzboob Mar. 13 at 9:33 PM

$CCCC Short-term pullback from $3.82 to $2.72 looks technical — stop-loss liquidations, not institutional distribution. Weekly MACD bullish crossover intact. Monte Carlo (1M simulations) projects median $3.64 (+34%) over 252 days, 61.3% probability of gain. IMO, sweet spot before bullsih movement is now around 2.50-2.55. @josegodoy whats your thoughts? Have a greak week end all!

1 · Reply

zawojak Mar. 13 at 7:50 PM

$CCCC I wonder who is selling this offback to bloody 2.40 next week 💩

0 · Reply

LabPsycho Mar. 13 at 2:24 PM

$CCCC @lelongduzboob Winning the Future Price Prediction Award today - even got the 10:30am time correct (so far). Impressive!

3 · Reply

lelongduzboob Mar. 12 at 9:12 PM

$CCCC IMO we should see a bullish movement tomorrow

1 · Reply

open_outcry Mar. 12 at 8:42 PM

$CCCC a key lesson of biotech/pharma investing: never expect positive clinical / scientific updates on their own to move SP in a positive direction. it happens sometimes with NDAs/other major milestones, but these stocks will push your patience to the limit most of the time. disciplined buying when SP is depressed and taking some profits on really good days (while maintaining your core position) is advisable to keep your sanity.

1 · Reply

zawojak Mar. 12 at 8:04 PM

$CCCC fu*k me :(

0 · Reply

lelongduzboob Mar. 11 at 7:54 PM

$CCCC

0 · Reply

C4 Therapeutics, Inc. (CCCC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mar 10, 2026, 7:49 AM EDT - 6 days ago

C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact

Mar 9, 2026, 4:01 PM EDT - 7 days ago

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 26, 2026, 7:00 AM EST - 18 days ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Feb 23, 2026, 7:10 AM EST - 21 days ago

C4 Therapeutics to Participate in Upcoming March Conferences

$C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma$

Feb 23, 2026, 7:00 AM EST - 21 days ago

C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

Feb 4, 2026, 7:00 AM EST - 5 weeks ago

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 14, 2026, 7:00 AM EST - 2 months ago

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

Nov 26, 2025, 6:27 AM EST - 3 months ago

Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss

Nov 25, 2025, 7:00 AM EST - 3 months ago

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 10:16 AM EST - 4 months ago

Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors

CWST ESPR INSP MNDY SITM

Nov 6, 2025, 7:00 AM EST - 4 months ago

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Oct 16, 2025, 7:08 AM EDT - 5 months ago

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

$C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma$

Oct 1, 2025, 7:00 AM EDT - 5 months ago

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma

Sep 22, 2025, 5:23 AM EDT - 6 months ago

C4 Therapeutics, Inc. - Special Call

Sep 20, 2025, 11:00 AM EDT - 6 months ago

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

Sep 4, 2025, 7:00 AM EDT - 6 months ago

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

Sep 3, 2025, 7:00 AM EDT - 6 months ago

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

Aug 7, 2025, 7:00 AM EDT - 7 months ago

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jun 16, 2025, 1:50 PM EDT - 9 months ago

C4 Therapeutics: An Entry Point If There's Ever Going To Be One

May 7, 2025, 7:00 AM EDT - 11 months ago

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Feb 27, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 24, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics to Participate in Upcoming March Investor Conferences

Dec 8, 2024, 12:30 PM EST - 1 year ago

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

Nov 20, 2024, 7:00 AM EST - 1 year ago

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

Oct 15, 2024, 4:01 PM EDT - 1 year ago

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

Oct 9, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

Sep 13, 2024, 10:00 AM EDT - 1 year ago

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 8, 2024, 6:05 PM EDT - 1 year ago

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 3, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

Aug 29, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Participate in Upcoming September Investor Conferences

Aug 1, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jul 16, 2024, 4:01 PM EDT - 1 year ago

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

Jul 8, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

Jun 10, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

May 8, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 9, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

Apr 8, 2024, 8:00 AM EDT - 2 years ago

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

Mar 5, 2024, 4:30 PM EST - 2 years ago

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

Mar 4, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

Feb 22, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Jan 9, 2024, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

Jan 4, 2024, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

Jan 4, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

$C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma$

Dec 12, 2023, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

Dec 12, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

$C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma$

Nov 28, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

Nov 20, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

Nov 1, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Oct 11, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myelom

zawojak Mar. 16 at 10:43 PM

0 · Reply

zawojak Mar. 16 at 7:24 PM

$CCCC shorts interest over 8.5M and growing, we are getting noticed.

0 · Reply

Stockboi_ Mar. 16 at 3:46 PM

$CCCC could be time for reversal here

0 · Reply

lelongduzboob Mar. 13 at 9:33 PM

1 · Reply

zawojak Mar. 13 at 7:50 PM

$CCCC I wonder who is selling this offback to bloody 2.40 next week 💩

0 · Reply

LabPsycho Mar. 13 at 2:24 PM

$CCCC @lelongduzboob Winning the Future Price Prediction Award today - even got the 10:30am time correct (so far). Impressive!

3 · Reply

lelongduzboob Mar. 12 at 9:12 PM

$CCCC IMO we should see a bullish movement tomorrow

1 · Reply

open_outcry Mar. 12 at 8:42 PM

1 · Reply

zawojak Mar. 12 at 8:04 PM

$CCCC fu*k me :(

0 · Reply

lelongduzboob Mar. 11 at 7:54 PM

$CCCC

0 · Reply

LabPsycho Mar. 11 at 6:02 PM

$CCCC @Andysss Yes, I find this a bit perplexing about this stock. I think it moves quite a bit considering how many shares they have - and moves on no news. Are they selling warrants into the buying? (Long term good thing but would hold this down for a while). As I have posted for many months, CCCC daily trade volume seems about 2-3X what I would expect based on comparable other biotechs which I find hard to reconcile.

1 · Reply

Andysss Mar. 11 at 2:11 PM

$CCCC most volatile stock I have owned. Beats CAPR pre des 3. Keep calm and hold

0 · Reply

zawojak Mar. 11 at 1:42 PM

$CCCC yep, unfortunately a fake breakout like in September 2025. Sorry guys not this time. If you sold at 3.80 congratulations.

1 · Reply

zawojak Mar. 10 at 9:57 PM

$CCCC all I need now is 97% run.

0 · Reply

outlawinvestor1 Mar. 10 at 9:01 PM

$CCCC calm down.

0 · Reply

carrotcarrot Mar. 10 at 8:55 PM

$CCCC wtf! WHY? 😭

0 · Reply

lelongduzboob Mar. 10 at 8:28 PM

$CCCC long term : https://seekingalpha.com/article/4880380-c4-therapeutics-stock-cemsidomide-progress-keeps-long-term-thesis-intact

0 · Reply

zawojak Mar. 10 at 5:07 PM

$CCCC wow it seems like we are heading back to 2's didn't expect this to happen so quick, painfully holding. Could recent pump and dump had anything to do with yesterday's inducement grants ?

0 · Reply

zawojak Mar. 10 at 3:39 PM

$CCCC RSI had to pop!

0 · Reply

LabPsycho Mar. 10 at 2:24 PM

$CCCC Outstanding post by @AllandaleCapital below. Everyone, including myself should map out a strategy for whatever stock they are trading as AllandaleCapital describes below and stick to it vs the usual emotional trading most of us have done. Write down your enter and entry points and when you bail (gain or loss) before buying a stock. I wish I could do it - Lol

0 · Reply

JuggernautRaider Mar. 10 at 1:17 PM

$CCCC buy and hold long… congrats to those who doubled their money in the last few weeks, but we’re just getting started 🚀

1 · Reply

open_outcry Mar. 10 at 12:47 PM

$CCCC another v bullish chat/presentation for investors this AM. always nice to have a gifted communicator as a CEO

1 · Reply

Market Cap	265.41M
Revenue (ttm)	35.95M
Net Income (ttm)	-104.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-292.04%
Debt to Equity Ratio	0.00

Volume	1,638,200
Avg Vol	2,113,448
Day's Range	N/A - N/A
Shares Out	97.58M
Stochastic %K	4%
Beta	2.85
Analysts	Strong Sell
Price Target	$11.57